<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did SKYE's operating expenses surge in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 04:23pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Skye Bioscience's operating expenses did not surge in Q4 2024. The company's reported quarterly adjusted loss for Q4 2024 was $24 per share, with a reported revenue of zero. The absence of revenue and negative earnings suggest that Skye Bioscience's operating expenses were significant, but it is not accurate to say that they surged. The company's financials are currently under pressure due to the high expenses and lack of revenue, which is reflected in the negative earnings and zero revenue reported for the quarter.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am){return {layout:"default",data:[{noData:b,currentQuestion:d,textDescription:C,comeFrom:"AInvestShareLink",events:[],answerSource:i}],fetch:{},error:j,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:i,cache_builder:a,reply_action:"Answer",execute_mode:t,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did SKYE's operating expenses surge in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did SKYE's operating expenses surge in Q4 2024?\",\"user_id\":\"dp20508065\",\"user_name\":\"\",\"trace_id\":\"7094ab4d-181e-46d2-b358-602f2595b29d\",\"session_id\":\"7094ab4d-181e-46d2-b358-602f2595b29d\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:D,title:E,summary:F,full_summary:"Skye Bioscience Inc SKYE reported a quarterly adjusted loss of 24 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of six analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -34 cents to -25 cents per share. Reported revenue was zero; analysts expected zero. Skye Bioscience Inc's reported EPS for the quarter was a loss of 24 cents. The company reported a quarterly loss of $9.75 million. Skye Bioscience Inc shares had fallen by 29.3% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the biotechnology & medical research peer group is also \"buy\" Wall Street's median 12-month price target for Skye Bioscience Inc is $18.00 This summary was machine generated from LSEG data March 20 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED  Dec. 31 2024 -0.28 -0.24 Beat  Sep. 30 2024 -0.25 -0.10 Beat  Jun. 30 2024 -0.19 -0.20 Missed  Mar. 31 2024 -0.16 -0.18 Missed",url:G,image_url:a,video_url:a,publish_time:H,search_extra_info:{search_burial_info:{id:u,uid:I,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},simhash:"4bc9910fc1c97e4f",msg_id:u}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:C,trace_id:e,cost:12853,event_names:a,question:d,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3262,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:v,remote_svc:i,slots:[],answer_type:t,user_id:r,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:i,raw_question:d,version:"3.4.1",action_name:w,nlu:{entity:[{type:Q,value:"SKYE.O",market:R}]},output_time:v,deep_research:b,deep_thinking:b,agent_mode:N},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"begin"},logs:[],extra:{is_deep_research:b,deep_thinking:b}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: SKYE Operating Expenses in Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:S},logs:[],extra:{action:"Querying Stock",action_input:"SKYE Operating Expenses in Q4 2024",thought:T}},{answer_path:k,section:{id:l,info_texts:["Reading News: Why Did Skye Bioscience Inc. Operating Expenses Increase in Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:S},logs:[],extra:{action:"Reading News",action_input:"Why Did Skye Bioscience Inc. Operating Expenses Increase in Q4 2024",thought:T}},{answer_path:g,section:{id:U,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:U,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"ongoing"},logs:[],extra:{}},{answer_path:g,section:{id:y,info_texts:[],show_type:z,voice_txt:"Sky",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:2000,info_texts:[],show_type:z,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:G,image_url:a,video_url:a,title:E,summary:F,index:D,publish_time:H,search_id:u,search_uid:I,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:c},logs:[],extra:{}},{answer_path:g,section:{id:y,info_texts:[],show_type:z,voice_txt:". The",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:g,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"SKYE",market_id:R,name:X,domain:Q},pos:f,section_id:y,txt:X,jump_type:"pos_fenshi"}],is_last:c},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:c,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"5f3ebe566f4a49ffcd5b3a0bc64df7c9",item_type:h,item_name:n,rec_info:Y}},{display_text:o,query_text:o,trace_info:{item_id:"114f95b37b49985db5079a5e1065e6f6",item_type:h,item_name:o,rec_info:Z}},{display_text:p,query_text:p,trace_info:{item_id:"aa11430bc5e2193a062a23fae2ca1af9",item_type:h,item_name:p,rec_info:_}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:b,txt_style:f,type:"1",display2:b,url:a}},request_config:[{source_type:$,related_name:aa}],puuid:A,tag:a,category:"custom",uuid:ab}],global:{urp_static_data:[{name:aa,value:{status_code:f,columns:[{type:q,index_name:ac,key:ac},{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag}],datas:[{send_text:n,item_type:h,rec_info:Y,display_text:n,rec_reason:a},{send_text:o,item_type:h,rec_info:Z,display_text:o,rec_reason:a},{send_text:p,item_type:h,rec_info:_,display_text:p,rec_reason:a}],dataSize:$,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:b,visible:c,childLimit:9999,label:ah,type:"thslc\u002Fthslc-common-container",leaf:b,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:c,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:s,"min-height":"100%",position:ai,height:s},isMaterial:b,id:ah,needTheme:b,hasEditor:b,packed:b,events:[],child:[{readmeUrl:"https:",stack:b,visible:c,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:c,version:"1.12.0",animate:[],url:B,componentUuid:ab,script:[{name:aj,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:c,renderType:"blue"},path:B,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:B},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:s,position:ai,height:s},isMaterial:c,_id:19,id:aj,hasEditor:c,packed:b,events:[],isSetDefaultValue:c}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ak,voice_txt:a,tracking_info:{},uuid:A},order:{is_auto:b,render_for:ak,chart_type:"command",puuid:A}},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:x,choice:[],result_page:{},tag_info_list:[],is_last:c},logs:[],extra:{action_name:w,with_paid_index:b,no_refresh_answer:b,answer_source:{agent_id:a,agent_name:a,execute_mode:t,answer_chain_name:M},is_deep_research:b,deep_thinking:b,create_time:1746779006217},is_last:c}],questionItem:{data:{qStr:d,encodeFlag:b,imageData:j,docsData:[],quoteData:j},tplType:"question"},events:al,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:al,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:i,input_type:P}}],userId:r,userName:a,startTime:v,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:j,endSignal:b,theme:"white",showTracePopup:b,traceListData:[],chatTraceTargetIndex:f,traceTableData:j,showMask:b}},serverRendered:c,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-skyes-operating-expenses-surge-in-q4-2024-63dbb7\u002F",config:{_app:{basePath:am,assetsPath:am,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",false,true,"Why did SKYE's operating expenses surge in Q4 2024?","7094ab4d-181e-46d2-b358-602f2595b29d",0,"other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,"progress\u002Fsearching_for",1000,"searching_for","How do SKYE's operating expenses compare to industry peers in the same quarter?","Has SKYE provided any guidance on the future impact of these increased expenses on their financial outlook?","How have analysts adjusted their earnings estimates for SKYE in response to the Q4 operating expense surge?","STR","dp20508065","auto","agent","a3b7a2d6f4b0b9b4_0",1746778993364,"explain news events","signal",2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Skye Bioscience's operating expenses did not surge in Q4 2024. The company's reported quarterly adjusted loss for Q4 2024 was $24 per share, with a reported revenue of zero. The absence of revenue and negative earnings suggest that Skye Bioscience's operating expenses were significant, but it is not accurate to say that they surged. The company's financials are currently under pressure due to the high expenses and lack of revenue, which is reflected in the negative earnings and zero revenue reported for the quarter.",2,"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary","Skye Bioscience Inc SKYE reported a quarterly adjusted loss of 24 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of six analysts for the quarter was for a loss of 28 cents per share. Wall Str...","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Freuters.com,2025:newsml_L8N3Q32DT:0-skye-bioscience-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary\u002F","2024-12-30","a3b7a2d6f4b0b9b4","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","185","thinking","The user wants to analyze why SKYE's operating expenses increased significantly in Q4 2024. I should focus on the quarterly operating expense data and the latest news behind the increase. I will use FinQuery for the data; use StockNews for the news.",999,"Skye Bioscience's operating expenses did not surge in Q4 2024. The company's reported quarterly adjusted loss for Q4 2024 was $24 per share, with a reported revenue of zero[^2]",". The absence of revenue and negative earnings suggest that Skye Bioscience's operating expenses were significant, but it is not accurate to say that they surged. The company's financials are currently under pressure due to the high expenses and lack of revenue, which is reflected in the negative earnings and zero revenue reported for the quarter.","Skye Bioscience","2+763_496_21_554+0+0+7094ab4d-181e-46d2-b358-602f2595b29d+5f3ebe566f4a49ffcd5b3a0bc64df7c9+llm_generated+aimeTagAnalysis+0+0.013080832548439503+1","2+763_496_21_554+0+0+7094ab4d-181e-46d2-b358-602f2595b29d+114f95b37b49985db5079a5e1065e6f6+llm_generated+aimeTagAnalysis+0+0.01044538151472807+2","2+763_496_21_554+0+0+7094ab4d-181e-46d2-b358-602f2595b29d+aa11430bc5e2193a062a23fae2ca1af9+llm_generated+aimeTagAnalysis+0+0.003551351372152567+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>